Glucosyltransferase Engineering Service
Diversification of the Glucosyltransferase (GT) Gene
GT catalyzes the sequential transfer of glucose from specific activated donors to specific acceptor molecules for the formation of oligosaccharides, polysaccharides, and other biomolecules. GT is a catalyst for glycan modification, complex glycans, etc. The synthesis of disaccharides, oligosaccharides, and polysaccharides involves several different GTs. Depending on the stereochemistry of the substrates and products of the reaction, GTs can be categorized as either convertases or retention enzymes. GTs are a highly diverse group of enzymes. GTs of bacterial, plant, animal, and viral origin have been classified into 116 families based on amino acid sequence similarity and catalytic mechanism.
CD BioGlyco utilizes cutting-edge gene editing technology to engineer GTs, providing a powerful approach to alter substrate specificity, improve catalytic efficiency, and develop novel glycan structures with customized properties. This advanced technology is crucial for a variety of applications, from producing complex carbohydrates for therapeutics to optimizing biofuel production.
Key Technologies
Our core expertise lies in the precise manipulation of genetic material to alter enzyme characteristics. This includes leveraging powerful gene editing systems for highly specific gene knock-in or knock-out, which is used to introduce or remove GT genes in host organisms. Additionally, we employ site-directed mutagenesis to introduce single or multiple amino acid substitutions, precisely tuning the enzyme's active site or allosteric regulation. High-throughput screening services and advanced protein expression systems in various hosts, including E. coli, yeast, and mammalian cells, are utilized to express and purify the engineered enzymes at high yields.
The Future of Glycoscience: Glucosyltransferase Engineering and Gene Editing Service
CD BioGlyco specializes in the development and application of technologies for gene editing. We are focusing on current hot gene editing topics and expanding our GT engineering service. We aim to provide better Gene Editing Services to our clients.
With the sequencing of biological genomes and continuous research in functional genomics, more and more GTs have been identified. We target the synthesis of sugars with specific functions and properties by altering GT expression to affect sugar synthesis through gene editing techniques. We edit a wide range of GT-related genes in animals, plants, and cancer. The editable GT genes include but are not limited to:
Fig.1 Types of editable GT genes. (CD BioGlyco)
- Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5) gene modification service
MGAT5 is associated with the synthesis of cell surface and secreted glycoprotein β1,6GlcNAc-branched N-linked glycans. MGAT5 has emerged as a promising target for cancer therapy and is involved in the stimulation of oncoproteins in cancer cells to promote carcinogenesis. We construct relevant gene expression vectors to regulate the expression of the MGAT5 gene. - Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase (GCNT3) gene modification service
GCNT3 has a variety of activities. For example, GCNT3 plays a key role in mucosal function and tumor migration and invasion. Researchers have found that silencing and functional inhibition of GCNT3 will greatly inhibit the migration and invasion of melanoma cells. This provides potential possibilities for the treatment of melanoma at the molecular level. We provide corresponding vector construction services. We develop and complete gene editing programs according to client needs. - Glycogen alpha-4-glucosyltransferase gene modification service
GTs play an important role in glycogen synthesis and include two types. We affect the expression of glycogen alpha-4-glucosyltransferase in animals by Overexpression and Knockdown. - Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (Mgat1) gene modification service
Mgat1 is essential for the conversion of high mannose to complex and heterogeneous N-glycan synthesis, initiating the formation of complex N-linked carbohydrates. We use an emerging editing technology to affect the synthesis of specific N-glycans through the Mgat1 knockdown. - Other GT gene modification services
UDP-glycosyltransferases (UGTs) catalyze the transfer of sugar groups from activated nucleotide sugar donors to acceptors to form glycosidic bonds. Glycosylation modification of natural products in plants is mainly achieved by UGTs. We also provide UGTs gene editing services.
Workflow
Publication Data
Journal: Horticulture research
IF: 8.5
Published: 2019
Results: This study applied genome editing in pomegranate hairy roots to target two GTs, PgUGT84A23 and PgUGT84A24, involved in hydrolyzable tannin (HT) biosynthesis. Dual knockouts (ugt84a23 ugt84a24) showed reduced punicalagins (major HTs) and accumulated gallic acid 3-O- and 4-O-glucosides, absent in controls or single knockouts. Transcriptome and real-time quantitative polymerase chain reaction (qPCR) analyses identified 11 upregulated UGTs, with PgUGT72BD1 characterized as a regiospecific enzyme producing gallic acid 4-O-glucoside. Phylogenetically grouped in UDP-dependent glycosyltransferases (UGTs) group E, PgUGT72BD1 exhibits high substrate affinity but low catalytic efficiency compared to the targeted UGTs and is root-specific. This work establishes genome editing as a tool for pomegranate functional genomics and germplasm improvement via phytochemical modification.
Fig.2 Gene editing of PgUGT84A23 and PgUGT84A24. (Chang, et al., 2019)
Applications
- GT is an important regulator of secondary metabolism in plants and is involved in the response to adversity stresses. The technologies for GT gene editing are used to optimize plant tolerance.
- Technologies for GT gene editing have an important role in protein structure analysis, GT catalytic mechanism, catalytic activity modification, and other studies.
- Technologies for GT gene editing achieve heterologous expression of recombinant proteins.
Advantages
- We have a wide range of GT genes that are edited, diverse services, and efficient technologies for gene editing. We aim to provide our clients with high-quality gene editing services.
- Technologies for GT gene editing help to study its effect on cancer cell migration and invasion, thus providing potential therapeutic targets for cancer treatment.
- Technologies for GT gene editing help to effectively improve the water solubility, pharmacological activity, and bioavailability of plant natural products, which is crucial for drug development of plant natural products.
Frequently Asked Questions
CD BioGlyco relies on a professional research team and advanced technologies to provide one-stop gene editing services according to your requirements. In addition to GT, we also provide Galactosyltransferase Engineering Service and Mannosyltransferase Engineering Service. Please feel free to contact us for more information.
Associated Services
We synthesize a wide range of complex carbohydrates to be used as substrates or standards.
We provide detailed structural analysis to understand the glycosylation patterns.
We develop stable cell lines that are optimized for the production of specific glycoconjugates.
Reference
- Chang, L.; et al. Effective genome editing and identification of a regiospecific gallic acid 4-O-glycosyltransferase in pomegranate (Punica granatum L.). Horticulture research. 2019, 6. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




